Briefs: Alembic Pharmaceuticals and Relonchem

Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025

Marksans Pharma updates on USFDA inspection at Verna, Goa manufacturing facility

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals

Marksans Pharma announces USFDA approval for Famotidine Tablets

Marksans' OTC Famotidine Tablets USP are acid reducers

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK

Marksans to acquire Tevapharm's bulk formulations business

Plans to double its manufacturing footprint to bolster the growth

Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr

The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.

Marksans announces US FDA approval for Acetaminophen Extended- Release tablets

The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India

Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr

The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant